Most Read Articles
Elaine Soliven, 20 Apr 2018
The use of high-flow oxygen therapy may reduce the need for escalation of care in infants with bronchiolitis compared with standard oxygen therapy, according to a recent study.
Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.

Physical activity, cardiorespiratory fitness reduce anxiety, panic, depressive symptoms

27 Sep 2017
Sweating it out once a week can still keep you as fit as another who works out daily, say researchers

Physical activity and cardiorespiratory fitness seem to reduce the odds of generalized anxiety, panic and depressive symptoms, a recent cross-sectional study has shown. In contrast, muscle strengthening activities exert no effects on these symptoms.

Males in the top tertile of moderate-to-vigorous physical activity (MVPA) had significantly lower chances of having generalized anxiety, panic and depressive symptoms, determined either through the Composite International Diagnostic Interview (CIDI) or through self-assessments (adjusted odds ratio [OR], 0.68; 95 percent CI, 0.48 to 0.96; p=0.02), than those in the bottom tier.

Females in the top MVPA tertile also had lower chances of manifesting the said symptoms than those in the bottom tertile (adjusted OR, 0.54; 0.29 to 1.02; p=0.05).

Compared with participants who had low fitness, those with high cardiorespiratory fitness had significantly lower odds of self-reported or CIDI-determined symptoms of general anxiety, panic and depression (adjusted OR, 0.60; 0.39 to 0.92; p=0.02) after adjusting or age, sex, ethnicity and other potential confounders.

In contrast, meeting the muscle strengthening guideline showed no significant associations with generalized anxiety, panic and depressive symptoms even after adjusting for potential confounders such as aerobic physical activities.

Taking all three variables into consideration, a dose-dependent association between the composite variable and CIDI-determined generalized anxiety, panic and depressive symptoms was observed.

Specifically, individuals who met the guidelines of one (OR, 0.61; 0.29 to 1.31; p=0.20), two (OR, 0.46; 0.19 to 1.11; p=0.08) or three (OR, 0.29; 0.10 to 0.77; p=0.01) of the above parameters had lower odds of manifesting the symptoms compared with those who fulfilled none of the guideline values.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 Apr 2018
The use of high-flow oxygen therapy may reduce the need for escalation of care in infants with bronchiolitis compared with standard oxygen therapy, according to a recent study.
Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.